The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients
Official Title: ARTSCAN VI Protocol Version 1, 2023-07-03 ARTSCAN VI - a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients
Study ID: NCT06248996
Brief Summary: There is an unmet need to personalise treatment for patients with head and neck squamous cell carcinoma (HNSCC) and to improve treatment results for patients with advanced disease. In this phase III study, HNSCC patients with prognostic factors indicating increased risk of treatment failure that are aimed for curative treatment with radiotherapy (RT) will be randomised between standard treatment (conventionally fractionated RT with final RT dose 68.0 Gy) and hyperfractionated RT (HFX-RT) with final RT dose 83.0 Gy. In order to find better prognostic and predictive tools the study also includes exploratory and translational analyses including evaluation of grade of hypoxia with Magnetic Resonance Imaging (MRI) and gene profiling by RNA-sequencing, tumour immune profiling, comparisons of global gene expression, gene aberrations and protein expression, and texture analyses of CT, FDG-PET and MRI images used during RT preparation and during patient follow-up. Patients with tumours with lower risk of recurrence, not eligible for randomisation in the study, can still participate in the translational parts of the study not investigating response to altered fractionation.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Gävle Hospital, Gävle, , Sweden
Sahlgrenska University Hospital, Göteborg, , Sweden
Jönköping Hospital, Jönköping, , Sweden
Karlstad Hospital, Karlstad, , Sweden
Linköping University hospital, Linköping, , Sweden
Lund University Hospital, Lund, , Sweden
Karolinska University Hospital, Stockholm, , Sweden
University Hospital, Umeå, , Sweden
Uppsala Accademical Hospital, Uppsala, , Sweden
Västmanlands Hospital Västerås, Västerås, , Sweden
Örebro University Hospital, Örebro, , Sweden
Name: Maria Gebre-Medhin, MD
Affiliation: Lund University Hospital
Role: PRINCIPAL_INVESTIGATOR